803 Reserve Champion Drive
Number 302
RemeGenix Inc.
Listen to this article
Recently launched RemeGenix aims to move quickly into the clinic with multifunctional drugs that address the biological mechanisms at the heart of neurodegeneration, not merely treat the symptoms. Its candidates for TBI are cyclic dipeptides structurally related to the major metabolic product of TRH (thyrotropin-releasing hormone). The drugs down-regulate several major injury pathways while up-regulating endogenous neuroprotective pathways.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
• By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains